Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.

By Alexandra Pecci • Jan. 29, 2026

Has Novavax cracked the code for survival in the vaccine arena?

The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.

By Meagan Parrish • Jan. 28, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

A potential gene therapy for heart failure is an approach decades in the making

Medera’s mid-stage heart failure gene therapy leverages a “master switch” that could widen the aperture of genetic medicine.

By Michael Gibney • Jan. 27, 2026

Biopharma layoffs surged last year, but 2026 is a chance to turn the page

Companies are adjusting to turbulence in the U.S. market, and more traditional job loss factors will likely be at play in the coming year.

By Kelly Bilodeau • Jan. 26, 2026

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

By Alivia Kaylor • Jan. 23, 2026

US drug pricing policies are ‘red lights’ for investors, and China beckons

Pricing policies like most-favored nation and the Inflation Reduction Act, as well as a destabilized FDA, are pushing investors to look outside the U.S.

By Michael Gibney • Jan. 22, 2026

Cancer R&D is thriving. Here are the areas to watch in 2026.

ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.

By Kelly Bilodeau • Jan. 21, 2026

The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?

The “trauma” faced by pharma execs in 2025 kept M&A at a low simmer, experts say, but as predictability returns, dealmaking could be turned up.

By Michael Gibney • Jan. 15, 2026

A biotech’s snakebite pill is drawing the US military’s interest

Backed by the Department of Defense, Ophirex is developing the first oral snakebite treatment, making on-the-ground treatment possible for the first time.

By Alexandra Pecci • Jan. 13, 2026

3 positive trends for Massachusetts’ biopharma sector

Despite a rocky landscape for the biotech industry nationally, Massachusetts has shown innovation growth and stronger funding than expected, which could bode well for the future.

By Michael Gibney • Jan. 13, 2026

What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug class. 

By Kelly Bilodeau • Jan. 12, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

By Michael Gibney • Jan. 8, 2026

5 FDA drug approvals to watch in 2026

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.

By Alexandra Pecci • Jan. 7, 2026

PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry

How pharma leaders believe the regulatory and investment market landscape will change in 2026. 

By Meagan Parrish • Jan. 6, 2026

3 of China’s most innovative pharma companies

The top Chinese drugmakers succeeding in both innovation and business savvy.

By Kelly Bilodeau • Jan. 5, 2026

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.

By Michael Gibney • Dec. 19, 2025

The leading GLP-1 contenders in pharma’s race for an obesity pill

Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape. 

By Alivia Kaylor • Dec. 18, 2025

3 key takeaways from the FDA’s new animal testing guidance

The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.

By Alexandra Pecci • Dec. 17, 2025

After years of debate, the Biosecure Act could be headed for Trump’s desk

The revised version of the bill softens compliance burdens between U.S. pharma firms and Chinese suppliers, but still has teeth.

By Kelly Bilodeau • Dec. 15, 2025

Amylyx pins its next hopes on a niche drug in the obesity space

A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.

By Meagan Parrish • Dec. 12, 2025

Pharma’s top deals in 2025

The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

By Michael Gibney • Dec. 11, 2025

Will 2026 be pharma’s M&A breakout year?

Big Pharma needs new products to replenish pipelines and has plenty of money in the coffers, but looming uncertainties could stymie dealmaking again.

By Kelly Bilodeau • Dec. 10, 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

By Michael Gibney • Dec. 9, 2025